DelveInsight Estimates a Promising Picture of JAK Inhibitors Clinical Trial Pipeline Landscape in the Coming Years as 40+ Key Pharma Players Bolster the Treatment Space

Key Takeaways from the JAK Inhibitors Pipeline Report Key Takeaways from the JAK Inhibitors Pipeline Report Request a sample and discover the recent advances in the JAK inhibitors market @JAK Inhibitors Competitive Landscape Report JAK Inhibitors Overview Janus kinase (JAK) inhibitors are small molecules of about 400 Da that can be administered orally. JAKs are phosphotransferases that bind to cytokine receptor intracellular domains and transmit signals to activate immune...

Key Takeaways from the JAK Inhibitors Pipeline Report

Request a sample and discover the recent advances in the JAK inhibitors market @JAK Inhibitors Competitive Landscape Report

JAK Inhibitors Overview

Janus kinase (JAK) inhibitors are small molecules of about 400 Da that can be administered orally. JAKs are phosphotransferases that bind to cytokine receptor intracellular domains and transmit signals to activate immune responses. Many interleukins, interferons, colony-stimulating factors, and hormone-like cytokines are among the cytokines that signal via JAKs (such as erythropoietin). These cytokine receptors communicate via various combinations of four JAKs (JAK1, JAK2, JAK3, and TYK2).

Tofacitinib and baricitinib (and oclacitinib in dogs) are first-generation jakinibs that block more than one JAK and thus inhibit many cytokines; these and other pan-jakinibs are being studied as therapeutic agents for a wide range of autoimmune diseases.

Several JAK inhibitor clinical trials are currently underway, ranging from cancer to autoimmune diseases like psoriasis. Several other JAK inhibitors may be effective in the treatment of multiple disorders in the future.

Find out more about FDA JAK inhibitors @JAK Inhibitor Drugs List

JAK Inhibitors Pipeline Analysis: Drug Profile

RINVOQ: AbbVie

RINVOQ, a selective JAK inhibitor discovered and developed by AbbVie scientists, is being studied in a variety of immune-mediated inflammatory diseases. RINVOQ inhibited JAK-1 more effectively than JAK-2, JAK-3, and TYK-2 in enzymatic and cellular assays. The importance of inhibiting specific JAK enzymes to therapeutic efficacy and safety is unknown at this time.

RINVOQ is currently being studied in phase III trials for colitis, giant cell arteritis, and Takayasu arteritis.

Filgotinib: Galapagos

Galapagos' Filgotinib (200 mg and 100 mg tablets) is approved and marketed in Europe and Japan for the treatment of adults with moderately to severely active RA who have not responded adequately or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib can be used alone or in conjunction with methotrexate (MTX). Filgotinib was submitted to the European Commission for an expanded indication for the treatment of adults with moderate to severe active ulcerative colitis who had an inadequate response, lost response to, or were intolerant to, conventional therapy or a biologic agent.

A snapshot of the JAK Inhibitors Pipeline Drugs mentioned in the report:

 

Learn more about the JAK inhibitor drugs @JAK Inhibitor Trials

Scope of the JAK Inhibitors Competitive Landscape Report 

Dive deep for rich insights into JAK inhibitor therapy; visit @FDA-approved JAK Inhibitors 

Table of Contents

 

For further information on the JAK inhibitors therapeutics assessment, reach out @JAK Inhibitor Therapy

Related Reports

Graft vs. Host Disease Market

Graft vs. Host Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key graft vs. host disease companies including ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, among others.

Graft vs. Host Disease Epidemiology Forecast

Graft vs. Host Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted graft vs. host disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Graft vs. Host Disease Pipeline

Graft vs. Host Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key graft vs. host disease companies, including Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, among others.

Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies, including Abivax, UCB, Sierra Oncology, Taisho, among others.

Myelofibrosis Pipeline

Myelofibrosis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myelofibrosis companies, including Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, among others.

Myelofibrosis Market

Myelofibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key myelofibrosis companies including Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, among others.

Other Trending Reports

Goitre Market |  Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 

Contact Us

Shruti Thakur 
[email protected]
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/delveinsight-estimates-a-promising-picture-of-jak-inhibitors-clinical-trial-pipeline-landscape-in-the-coming-years-as-40-key-pharma-players-bolster-the-treatment-space-301678000.html